SCHEMBL4664262

SCHEMBL4664262

CN(C)CCn1ccc2cc(-c3cc(Nc4ccc(NS(=O)(=O)c5ccccc5F)cc4)ncn3)ccc21

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.53
BPTF Q12830 8/20 0.51
EGFR P00533 6/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666058 0.95 BPTF (0.52) HTR6BPTFEGFR
SCHEMBL4665735 0.92 BPTF (0.50) HTR6BPTFEGFR
SCHEMBL4665741 0.91 BPTF (0.49) HTR6BPTFEGFR
Formic Acid SCHEMBL4664240 0.89 HTR6 (0.51) HTR6BPTFEGFR
Formic Acid SCHEMBL4666201 0.88 BPTF (0.46) HTR6BPTFEGFR
SCHEMBL4665761 0.87 BPTF (0.51) HTR6BPTFEGFR
SCHEMBL4667461 0.87 PRF1 (0.46)
SCHEMBL4663918 0.87 BPTF (0.51) HTR6BPTFEGFR
Formic Acid SCHEMBL4663920 0.86 HTR6 (0.46) HTR6BPTFEGFR
Formic Acid SCHEMBL4664281 0.86 HTR6 (0.46) HTR6BPTFEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 HTR6 826/4885BPTF 2862/4885EGFR 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.